These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24325566)

  • 1. Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.
    Tsao NW; Shojania K; Marra CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):9-18. PubMed ID: 24325566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.
    Saraux A; Gossec L; Goupille P; Bregman B; Boccard E; Dupont D; Beresniak A
    Rheumatology (Oxford); 2010 Apr; 49(4):733-40. PubMed ID: 20081224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving patient outlook in rheumatoid arthritis: experience with abatacept.
    Coughlin M
    J Am Acad Nurse Pract; 2008 Oct; 20(10):486-95. PubMed ID: 19128344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Abatacept in the treatment of active rheumatoid arthritis].
    Nielsen H; Hansen A
    Ugeskr Laeger; 2009 Jan; 171(4):214-7. PubMed ID: 19174034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
    Shergy WJ
    Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
    Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
    Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW; Bansback NJ; Shojania K; Marra CA
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Productivity cost model of the treatment of rheumatoid arthritis with abatacept.
    Burton WN; Morrison A; Yuan Y; Li T; Marioni RE; Maclean R
    J Med Econ; 2008; 11(1):3-21. PubMed ID: 19450107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.